Loading ETF research
Fetching the latest fund profile, holdings, and market data.
Fetching the latest fund profile, holdings, and market data.

Chicago Board Options Exchange · Equity
$42.35
−$0.76 · -1.76%
· Aug 24, 10:31 AM ET
$42.35
Regular session−$0.76 · -1.76%
· Aug 24, 10:31 AM ET
$42.35
−$0.76 · -1.76%
Regular session · ET · Market data may be delayed.
This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. The core investment thesis of the fund centers on companies engaged in genomic advancements. Specifically, it seeks out firms that the investment manager believes are fundamentally dedicated to, or are poised to significantly benefit from, efforts to prolong and enhance the overall quality of life for both humans and animals. This is accomplished by integrating cutting-edge technological and scientific innovations, improvements, and breakthroughs in the field of genomics directly into their business models and operations.
Fund assets
32.4M USD
Expense ratio
0.50%
NAV
$43.20
Average volume
1.92K
Volume
1.5K
Day range
$42.35 – $43.11
52-week range
$29.32 – $43.11
Previous close
$43.11
Portfolio
Holdings data updated Aug 24, 2026.
Portfolio composition
Fund income
Dec 30, 2025
Irregular
Dec 30, 2025
Jan 8, 2026
$0.1433
Dec 30, 2021
Monthly
Dec 31, 2021
Jan 7, 2022
$0.0039
Dec 13, 2021
Annual
Dec 14, 2021
Dec 21, 2021
$0.1142
Dec 14, 2020
Annual
Dec 15, 2020
Dec 23, 2020
$0.0518
Latest coverage
No ETF news is currently available.
More funds
Continue in GoAI
Connect this ETF with broader market context and continue your research in GoAI.
ETF data may be delayed, incomplete, or revised. Holdings and exposures change over time. Historical performance does not guarantee future results. This page is for informational and educational purposes only and does not constitute investment advice or a recommendation.